Paclitaxel-induced dermal hypersensitivity lesions: 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography/computed tomography

• Main Authors: Inci Uslu Biner, Ebru Tatci, Berna Akinci Ozyurek, Ozlem Ozmen
• Format: Article
• Language: English
• Published: Wolters Kluwer Medknow Publications 2018-01-01
• Series: Lung India
• Subjects: 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography/computed tomography; hypersensitivity reaction; lung cancer; paclitaxel
• Online Access: http://www.lungindia.com/article.asp?issn=0970-2113;year=2018;volume=35;issue=2;spage=157;epage=159;aulast=Biner

Paclitaxel is frequently used for the treatment of patients with nonsmall cell lung cancer. Hypersensitivity reactions (HSRs) have been one of the toxicities observed with administration of paclitaxel. Here, we presented a case of a 49-year-old man with a history of right lung mass proven by biopsy to be a nonsmall cell lung cancer (squamous cell carcinoma) who developed HSR during therapy. In addition to the hypermetabolic primary malignancy, a positron emission tomography/computed tomography (PET/CT) scan showed multiple hypermetabolic skin lesions at several parts of the body. These cutaneous lesions were resolved in the restaging PET/CT scan performed after completion of the six cycles of chemotherapy. This is the first documented case of comparative PET/CT findings of a paclitaxel-induced hypersensitivity.